Pfizer Takes 3% Stake In Sosei On Back Of Heptares GPCR Deal
This article was originally published in Scrip
Heptares Therapeutics, a Sosei Group subsidiary, has entered a deal to apply its drug discovery technology to 10 G protein-coupled receptor (GPCR) targets selected by Pfizer Inc. across a number therapeutic areas. The deal also sees Pfizer acquiring a 3% equity stake in Sosei.
Register for our free email digests: